IDEAYA Biosciences (NASDAQ:IDYA) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a research note issued to investors on Tuesday morning,Benzinga reports.

Several other equities research analysts also recently commented on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, September 24th. Wedbush restated an “outperform” rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday. UBS Group started coverage on shares of IDEAYA Biosciences in a report on Thursday, October 24th. They issued a “buy” rating and a $50.00 target price for the company. Stifel Nicolaus increased their price target on shares of IDEAYA Biosciences from $63.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. Finally, Oppenheimer reissued an “outperform” rating and set a $53.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.67.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA opened at $26.33 on Tuesday. The firm has a market capitalization of $2.28 billion, a P/E ratio of -11.30 and a beta of 0.79. IDEAYA Biosciences has a one year low of $24.72 and a one year high of $47.74. The company’s 50-day simple moving average is $28.57 and its 200 day simple moving average is $34.23.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same quarter in the previous year, the business earned ($0.46) EPS. On average, equities research analysts expect that IDEAYA Biosciences will post -2.45 earnings per share for the current fiscal year.

Institutional Trading of IDEAYA Biosciences

A number of hedge funds have recently bought and sold shares of IDYA. State Street Corp grew its stake in shares of IDEAYA Biosciences by 15.4% during the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company’s stock valued at $105,112,000 after purchasing an additional 443,640 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of IDEAYA Biosciences by 38.4% in the second quarter. Nisa Investment Advisors LLC now owns 3,340 shares of the company’s stock worth $117,000 after buying an additional 927 shares during the last quarter. Quest Partners LLC bought a new stake in IDEAYA Biosciences during the second quarter valued at approximately $41,000. Scientech Research LLC increased its holdings in IDEAYA Biosciences by 362.3% during the second quarter. Scientech Research LLC now owns 27,708 shares of the company’s stock valued at $973,000 after buying an additional 21,714 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. raised its position in IDEAYA Biosciences by 34.4% in the second quarter. D. E. Shaw & Co. Inc. now owns 884,538 shares of the company’s stock worth $31,056,000 after acquiring an additional 226,514 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.